


CORRECTION

Open Access



Correction: The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons

Jace Jones-Tabah^{1,2}, Kathy He¹, Nathan Karpilovsky¹, Konstantin Senkevich^{1,2}, Ghislaine Deyab¹, Isabella Pietrantonio¹, Thomas Goiran¹, Yuting Cousineau², Daria Nikanorova⁴, Taylor Goldsmith³, Esther del Cid Pellitero¹, Carol X.-Q. Chen³, Wen Luo³, Zhipeng You³, Narges Abdian³, Jamil Ahmad^{1,2}, Jennifer A. Ruskey^{1,2}, Farnaz Asayesh^{1,5}, Dan Spiegelman¹, Stanley Fahn⁶, Cheryl Waters⁶, Oury Monchi^{2,7,8}, Yves Dauvilliers⁹, Nicolas Dupré^{10,11}, Irina Miliukhina¹², Alla Timofeeva¹³, Anton Emelyanov¹³, Sofya Pchelina¹³, Lior Greenbaum¹⁴, Sharon Hassin-Baer^{14,15,16}, Roy N. Alcalay^{6,17}, Austen Milnerwood², Thomas M. Durcan³, Ziv Gan-Or^{1,5} and Edward A. Fon^{1,2*} 

The original article can be found online at <https://doi.org/10.1186/s13024-024-00779-9>.

*Correspondence:

Edward A. Fon
ted.fon@mcgill.ca

¹ Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada

² Department of Neurology and Neurosurgery, McGill University, Montréal, Canada

³ Early Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada

⁴ Research Department, Bioinformatics Institute, Saint-Petersburg, Russia

⁵ Department of Human Genetics, McGill University, Montréal, Canada

⁶ Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA

⁷ Département de Radiologie, Radio-Oncologie Et Médecine Nucléaire, Université de Montréal, Montréal, QC, Canada

⁸ Centre de Recherche de L'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada

⁹ Sleep Unit, Department of Neurology, National Reference Center for Narcolepsy, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France

¹⁰ Neuroscience Axis, CHU de Québec – Université Laval, Quebec City G1V 4G2, Canada

Correction: Mol Neurodegeneration 19, 88 (2024)
<https://doi.org/10.1186/s13024-024-00779-9>

The authors wish to note the Grant ID, MFFF – 007905 relating to the mentioned grants to ZGO and EAF from the Michael J. Fox Foundation which was mistakenly omitted from the original article [1].

¹¹ Department of Medicine, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada

¹² Institute of the Human Brain of RAS, St. Petersburg, Russia

¹³ First Pavlov State Medical, University of St. Petersburg, Saint-Petersburg, Russia

¹⁴ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

¹⁵ The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

¹⁶ Department of Neurology, The Movement Disorders Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

¹⁷ Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

The authors also wish to note that Lior Greenbaum is only affiliated to affiliation #14 (Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel).

Published online: 18 December 2024

Reference

1. Jones-Tabah J, He K, Karpilovsky N, et al. The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons. *Mol Neurodegeneration*. 2024;19:88. <https://doi.org/10.1186/s13024-024-00779-9>.